Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC - report from ESMO2023

Professor Nicolas Girard explains primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer. Video: https://medicaldigest.org/scientific-contents/interview:mivantamab-plus-chemotherapy-new-first-line-standard-care-egfr-exon-20-insertion-mutated-advanced-nsclchttps://medicaldigest.org/scientific-contents/interview:mivantamab-plus-chemotherapy-new-first-line-standard-care-egfr-exon-20-insertion-mutated-advanced-nsclc